CLLS.O Overview

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Wall Street analysts forecast CLLS.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS.O is7.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cellectis SA revenue for the last quarter amounts to NaN USD, decreased

Cellectis SA. EPS for the last quarter amounts to USD, decreased

Cellectis SA (CLLS.O) has 229 emplpoyees as of April 26 2026.

Today CLLS.O has the market capitalization of 402.36M USD.